{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:56:36Z","timestamp":1783515396021,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The HIV-1 Tat protein is essential for virus replication and spread and is therefore a potential target for anti-HIV therapy. Anti-Tat antibodies have been shown to slow HIV disease progression and improve antiretroviral therapy (ART) efficacy. Long-term ART results in partial reconstitution of the immune system in people living with HIV-1 (PLWH) who start treatment in the chronic phase of infection, but the impact of ART initiation in the acute phase of infection is less studied. In this study, we investigate the effect of initiating ART in acute phase infection on the production of anti-Tat antibodies and on T-cell activation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Anti-Tat IgA, IgG, and IgM titres were evaluated longitudinally by enzyme-linked immunosorbent assay in plasma samples collected from 34 women who started ART immediately following the detection of acute HIV-1 infection. Total HIV-1 DNA measurements were performed by droplet digital PCR from total peripheral blood mononuclear cells at 1-year post ART initiation. T-cell activation was assessed longitudinally by analysis of the expression of HLA-DR and CD38 on CD4+ and CD8+ T-cells using flow cytometry. We also explored the association between anti-Tat antibody titres and CD4+ T-cell counts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The data showed that anti-Tat IgG and IgM titres had decreased significantly after 12 months of treatment (p=0.0001) with no correlation between anti-Tat IgA, IgG or IgM and CD4+ T-cell counts (r= -0.09 to 0.2, p&amp;gt;0.05).  There was no correlation between anti-Tat antibody levels and total HIV-1 DNA levels at ART initiation (r= 0.2143, p= 0. 6191) or after 12 months post-ART (r= -0. 2857, p= 0, 5008). There was a significant decrease in CD8+ T-cell activation between the baseline (day 1 on ART) and 12 months post-ART (p=0.0129).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and conclusion<\/jats:title><jats:p>These findings suggest early initiation of ART reduces the production of anti-Tat antibodies and reduces CD8+ T-cell activation. Further studies on the impact of early ART on antiviral immune responses are needed and may shed light on mechanisms of optimal immune reconstitution and reservoir control in PLWH.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1564960","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:15:07Z","timestamp":1750220107000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiretroviral therapy initiated during acute infection in women with HIV-1 clade C reduces anti-Tat antibody production and lowers CD8+ T cell activation"],"prefix":"10.3389","volume":"16","author":[{"given":"Thandeka I.","family":"Kubheka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewreshini","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavidha","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thumbi","family":"Ndung\u2019u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nompumelelo P.","family":"Mkhwanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0118","article-title":"Barriers for HIV cure: the latent reservoir","volume":"34","author":"Castro-Gonzalez","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.2015.79.issue-2","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.945956","article-title":"The reservoir of latent HIV","volume":"12","author":"Chen","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142640","article-title":"HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy","volume":"6","author":"Stevenson","year":"2021","journal-title":"JCI Insight"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666170704130635","article-title":"The HIV-1 tat protein: mechanism of action and target for HIV-1 cure strategies","volume":"23","author":"Rice","year":"2017","journal-title":"Curr Pharm Des"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/330489a0","article-title":"Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product","volume":"330","author":"Kao","year":"1987","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/v12040415","article-title":"Tat-based therapies as an adjuvant for an HIV-1 functional cure","volume":"12","author":"Jin","year":"2020","journal-title":"Viruses"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06648-11","article-title":"The viral protein Tat can inhibit the establishment of HIV-1 latency","volume":"86","author":"Donahue","year":"2012","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01383-08","article-title":"Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency","volume":"82","author":"Pearson","year":"2008","journal-title":"J Virol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077746","article-title":"The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses","volume":"8","author":"Nicoli","year":"2013","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048781","article-title":"HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies","volume":"7","author":"Monini","year":"2012","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2089119","article-title":"HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine","volume":"21","author":"Cafaro","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.180\/14760584.2020.1712199","article-title":"HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy","volume":"19","author":"Moretti","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"B16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/vaccines7030099","article-title":"Anti-tat immunity in HIV-1 infection: effects of naturally occurring and vaccine-induced antibodies against tat on the course of the disease","volume":"7","author":"Cafaro","year":"2019","journal-title":"Vaccines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1742-4690-11-49","article-title":"The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study","volume":"11","author":"Bellino","year":"2014","journal-title":"Retrovirology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12977-016-0251-3","article-title":"Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies\/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I\/II randomized controlled clinical trial","volume":"13","author":"Loret","year":"2016","journal-title":"Retrovirology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12879-016-1647-3","article-title":"Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort","volume":"16","author":"Nicoli","year":"2016","journal-title":"BMC Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30146-7","article-title":"Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study","volume":"5","author":"Dong","year":"2018","journal-title":"Lancet HIV"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau2798","article-title":"A FRESH approach: Combining basic science and social good","volume":"3","author":"Ndung\u2019u","year":"2018","journal-title":"Sci Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix225","article-title":"HIV antibody level as a marker of HIV persistence and low-level viral replication","volume":"216","author":"Keating","year":"2017","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28242-y","article-title":"Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro","volume":"8","author":"Devito","year":"2018","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.3.1769","article-title":"Inhibition of HIV-1 infectivity through an innate mechanism involving naturally occurring IgM anti-leukocyte autoantibodies","volume":"180","author":"Lobo","year":"2008","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00374-14","article-title":"Influenza virus-specific neutralizing IgM antibodies persist for a lifetime","volume":"21","author":"Skountzou","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013540","article-title":"Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART","volume":"5","author":"Ensoli","year":"2010","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28","doi-asserted-by":"publisher","first-page":"103306","DOI":"10.1016\/j.ebiom.2021.103306","article-title":"Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART","volume":"66","author":"Tripiciano","year":"2021","journal-title":"eBioMedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"RP96617","DOI":"10.7554\/eLife.96617.3","article-title":"Differences in HIV-1 reservoir size, landscape characteristics and decay dynamics in acute and chronic treated HIV-1 Clade C infection","volume":"13","author":"Reddy","year":"2024","journal-title":"eLife"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804192105","article-title":"HIV rebounds from latently infected cells, rather than from continuing low-level replication","volume":"105","author":"Joos","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/COH.0000000000000122","article-title":"How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs","volume":"10","author":"Ananworanich","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738743","article-title":"Antigen presenting cells contribute to persistent immune activation despite antiretroviral therapy initiation during hyperacute HIV-1 infection","volume":"12","author":"Naidoo","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/COH.0000000000000118","article-title":"Impact of antiretroviral therapy (ART) timing on chronic immune activation\/inflammation and end-organ damage","volume":"10","author":"Rajasuriar","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01896","article-title":"CD8(+) T-cell response to HIV infection in the era of antiretroviral therapy","volume":"10","author":"Perdomo-Celis","year":"2019","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1564960\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:15:09Z","timestamp":1750220109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1564960\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2025.1564960"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1564960","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1564960"}}